Results 231 to 240 of about 827,803 (310)

Evaluation of Anemia Management in a Contemporary Population of Patients With Chronic Kidney Disease in Canada Since the Publication of Target Hemoglobin Trials: A Retrospective Observational Cohort Study. [PDF]

Can J Kidney Health Dis
Birks P, Canney M, Djurdjev O, Induruwage D, Atiquzzaman M, Levin A.   +5 more
europepmc   +1 more source

A Novel IDO1/NE Dual Inhibitor, IMM‐H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression

Advanced Science, EarlyView.
IMM‐H018, a dual IDO1/NE inhibitor, demonstrates potent therapeutic efficacy in sepsis by simultaneously targeting excessive inflammation and immune dysfunction. It prevents both primary and secondary sepsis through anti‐inflammatory, immune‐restoring, and renoprotective mechanisms, reducing organ damage, improving immune homeostasis, preserving kidney
Yi Zhou, Xiaodi Zhao, Xiaochen Pan, Zhiling Ma, Huaqing Cui, Hui Wen, Peng Wang, Xiufeng Liao, Kejie Qin, Yuchen Wang, Li Sheng, Sen Zhang   +11 more
wiley   +1 more source

Chronic but not Transient Anemia Is Associated With Atrial Fibrillation Recurrence After Catheter Ablation. [PDF]

J Arrhythm
Kasch MG, Snæbjörnsson NT, Riis-Vestergaard LD, Rached R, Christensen DM, Binding C, Elmegaard M, Hashiba M, Nielsen SK, Lambert M, Torp-Pedersen C, Schou M, Gislason G, Mohamed AA.   +13 more
europepmc   +1 more source

Microenvironment‐Responsive Nanomedicine Enables Vertical Modulation of Mitochondrial Pathological Networks in Myocardial Ischemia–Reperfusion Injury

Advanced Science, EarlyView.
A mitochondria‐targeted, microenvironment‐responsive nanoplatform enables pH/ROS‐triggered co‐delivery of berberine and isoliensinine to orchestrate ROS scavenging, inflammation suppression, and apoptosis inhibition. This vertical modulation of mitochondrial pathological networks preserves mitochondrial function and effectively mitigates myocardial ...
Jue Wang, Jia Zhou, Wenqin Yuan, Tianjiao Zhao, Yunying Huang, Yingci Xia, Yuting Lin, Fei Li, Qiong Huang, Chong Liu, Kelong Ai, Qun Qin   +11 more
wiley   +1 more source

Hemoglobin Trajectories on SGLT2 Inhibitor Therapy in Heart Failure: Anemia Marks Adverse Prognosis While Erythrocytosis Is Transient and Not Associated with Adverse Outcomes. [PDF]

J Clin Med
Jurin I, Hadžibegović I, Pavlov M, Marović M, Čikara T, Lucijanić M.   +5 more
europepmc   +1 more source

Charting the Future of Stereoselective Carbohydrate Synthesis: The Essential Role of Cross‐Disciplinary Innovation

Advanced Science, EarlyView.
Cross‐disciplinary endeavors are blossoming across the broad chemical sciences. This perspective provides a glimpse into the rewarding interdisciplinary journey taken by the Charles Loh research group in pioneering the σ‐hole based catalytic glycosylation strategy.
Charles C. J. Loh
wiley   +1 more source

Proactive iron supplementation alone in patients on chronic hemodialysis is not sufficient. [PDF]

Ren Fail
Pribelszki P, Szász M, Tapolyai M.
europepmc   +1 more source

Optimized Lipid Nanoparticles with Tail‐Modified Ionizable Lipids for Safer mRNA Delivery

Advanced Science, EarlyView.
Systematic engineering of hydrophobic tail architecture in vitamin B5‐derived ionizable lipids establishes a comprehensive structure–activity relationship framework for mRNA delivery. Combined lipidtail and formulation optimization identifies TM1‐OPT3‐C, a lipid nanoparticle platform that improves efficacy–safety balance through efficient mRNA delivery,
Seo‐Hyeon Bae, Jisun Lee, Jae‐Hun Ahn, Hosam Choi, Huijeong Choi, Jungmin Kim, Minho Kang, Ho Rim Oh, So Hyun Park, Eun Young Oh, Sanghyuk Jeon, Yeeun Lee, Yu‐Sun Lee, Na‐Young Lee, Hee‐Jin Bae, Jina Kwak, Jooil Kim, Nakyung Lee, Beomsun Kang, Ji‐Hye Kim, Eunsaem Song, Daesub Song, Hyunho Yoon, Sang‐Myeong Lee, Hyewon Youn, Kiyoun Lee, Byeong‐Cheol Kang, Jae‐Hwan Nam   +27 more
wiley   +1 more source

SGLT2 inhibitors and secondary polycythemia: a systematic review and meta-analysis of hematologic effects in patients with type 2 diabetes. [PDF]

Eur J Clin Pharmacol
Ali EAH, Rabadi M, Aweer RA, Subahi E, Abdelmahmuod EA, Alshurafa A, Abdulgayoom M, Mudarres MF, Elshaikh U, Al-Mashdali A, Mohamed S.   +10 more
europepmc   +1 more source